PentraSorb C-Reactive Protein: Characterization of the Selective C-Reactive Protein Adsorber Resin.
Apheresis
C-reactive protein
Immunoadsorption
Myocardial infarction
Journal
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
ISSN: 1744-9987
Titre abrégé: Ther Apher Dial
Pays: Australia
ID NLM: 101181252
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
16
11
2018
revised:
24
01
2019
accepted:
28
01
2019
pubmed:
31
1
2019
medline:
23
2
2020
entrez:
31
1
2019
Statut:
ppublish
Résumé
C-reactive protein (CRP) is well known as a general marker of inflammation. It furthermore represents a reliable risk factor for cardiac events and mediates tissue damage in acute myocardial infarction (AMI). It has been demonstrated that selective CRP depletion by extracorporeal apheresis in a porcine AMI model had beneficial effects on the infarcted area and the cardiac output. We therefore developed a novel adsorber for CRP apheresis from human plasma (PentraSorb CRP). It is intended for use in the clinic as therapy for patients suffering from AMI or other acute inflammatory diseases with elevated CRP plasma levels. The PentraSorb resin specifically bound CRP from human blood plasma and almost no other proteins as determined via Sodium dodecyl sulfate polyacrylamide gel electropheresis (SDS-PAGE). The resin further efficiently and selectively depleted CRP from plasma with low as well as high CRP concentrations (10-100 mg/L) at different flow rates, ranging from 17 to 40 mL/min. The resin was regenerable for up to 200 times without losing its CRP binding capacity or affecting biocompatibility. The depletion of CRP from plasma was comparable between the utilized small-scale column (0.5 mL resin) and the PentraSorb CRP adsorber (20 mL resin volume). The established features can therefore be applied to the clinical setting. In summary, PentraSorb CRP provides a novel, specific, and efficient CRP-binding resin that could be used in apheresis therapy for patients suffering from inflammatory diseases such as AMI, stroke, acute pancreatitis, and Crohn's disease.
Identifiants
pubmed: 30697961
doi: 10.1111/1744-9987.12796
doi:
Substances chimiques
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
474-481Subventions
Organisme : Pentracor GmbH
Informations de copyright
© 2019 International Society for Apheresis, Japanese Society for Apheresis, and Japanese Society for Dialysis Therapy.
Références
Mortensen RF. C-reactive protein, inflammation, and innate immunity. Immunol Res 2001;24:163-76.
de Beer FC, Hind CR, Fox KM, Allan RM, Maseri A, Pepys MB. Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. Br Heart J 1982;47:239-43.
Dedobbeleer C, Melot C, Renard M. C-reactive protein increase in acute myocardial infarction. Acta Cardiol 2004;59:291-6.
Cushman M, Arnold AM, Psaty BM et al. C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the cardiovascular health study. Circulation 2005;112:25-31.
Koenig W, Sund M, Frohlich M et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (monitoring trends and determinants in cardiovascular disease) Augsburg cohort study, 1984 to 1992. Circulation 1999;99:237-42.
Pai JK, Pischon T, Ma J et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004;351:2599-610.
Liu D, Qi X, Li Q et al. Increased complements and high-sensitivity C-reactive protein predict heart failure in acute myocardial infarction. Biomed Rep 2016;5:761-5.
Sanchez PL, Rodriguez MV, Villacorta E et al. Kinetics of C-reactive protein release in different forms of acute coronary syndrome. Rev Esp Cardiol 2006;59:441-7.
Dimitrijevic O, Stojcevski BD, Ignjatovic S, Singh NM. Serial measurements of C-reactive protein after acute myocardial infarction in predicting one-year outcome. Int Heart J 2006;47:833-42.
Stumpf C, Sheriff A, Zimmermann S et al. C-reactive protein levels predict systolic heart failure and outcome in patients with first ST-elevation myocardial infarction treated with coronary angioplasty. Arch Med Sci 2017;13:1086-93.
Suleiman M, Khatib R, Agmon Y et al. Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction predictive role of C-reactive protein. J Am Coll Cardiol 2006;47:962-8.
Lagrand WK, Niessen HW, Wolbink GJ et al. C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation 1997;95:97-103.
Nijmeijer R, Lagrand WK, Lubbers YT et al. C-reactive protein activates complement in infarcted human myocardium. Am J Pathol 2003;163:269-75.
Griselli M, Herbert J, Hutchinson WL et al. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med 1999;190:1733-40.
Pepys MB, Hirschfield GM, Tennent GA et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 2006;440:1217-21.
Barrett TD, Hennan JK, Marks RM, Lucchesi BR. C-reactive-protein-associated increase in myocardial infarct size after ischemia/reperfusion. J Pharmacol Exp Ther 2002;303:1007-13.
Ridker PM, Cannon CP, Morrow D et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20-8.
Slagman AC, Bock C, Abdel-Aty H et al. Specific removal of C-reactive protein by apheresis in a porcine cardiac infarction model. Blood Purif 2011;31:9-17.
Sheriff A, Schindler R, Vogt B et al. Selective apheresis of C-reactive protein: a new therapeutic option in myocardial infarction? J Clin Apher 2015;30:15-21.
Berton G, Cordiano R, Palmieri R, Pianca S, Pagliara V, Palatini P. C-reactive protein in acute myocardial infarction: association with heart failure. Am Heart J 2003;145:1094-101.
Heusch G, Libby P, Gersh B et al. Cardiovascular remodelling in coronary artery disease and heart failure. Lancet 2014;383:1933-43.
Miller TD, Christian TF, Hopfenspirger MR, Hodge DO, Gersh BJ, Gibbons RJ. Infarct size after acute myocardial infarction measured by quantitative tomographic 99mTc sestamibi imaging predicts subsequent mortality. Circulation 1995;92:334-41.
Krijnen PA, Meischl C, Nijmeijer R, Visser CA, Hack CE, Niessen HW. Inhibition of sPLA2-IIA, C-reactive protein or complement: new therapy for patients with acute myocardial infarction? Cardiovasc Hematol Disord Drug Targets 2006;6:113-23.
Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet 2018;391:319-28.
Kitsis RN, Jialal I. Limiting myocardial damage during acute myocardial infarction by inhibiting C-reactive protein. N Engl J Med 2006;355:513-5.
Cray C, Zaias J, Altman NH. Acute phase response in animals: a review. Comp Med 2009;59:517-26.
Lee RT, Takagahara I, Lee YC. Mapping the binding areas of human C-reactive protein for phosphorylcholine and polycationic compounds. Relationship between the two types of binding sites. J Biol Chem 2002;277:225-32.
Feingold K, Grunfeld C. Lipoprotein apheresis. In: De Groot LJ, Chrousos G, Dungan K et al., eds. Endotext. South Dartmouth: MDText.com, Inc., 2000.
Kojima S, Harada-Shiba M, Nomura S et al. Effect of nafamostat mesilate on bradykinin generation during low-density lipoprotein apheresis using a dextran sulfate cellulose column. ASAIO Trans 1991;37:644-8.
Koga N, Nagano T, Sato T, Kagasawa K. Anaphylactoid reactions and bradykinin generation in patients treated with LDL-apheresis and an ACE inhibitor. ASAIO J 1993;39:M288-91.
Ries W, Sheriff A, Heigl F, Zimmermann O, Garlichs CD, Torzewski J. “First in man”: case report of selective C-reactive protein apheresis in a patient with acute ST segment elevation myocardial infarction. Case Rep Cardiol 2018;2018:4.